Retension Pharmaceuticals (NASDAQ:RTSN – Get Free Report) was upgraded by equities researchers at Wall Street Zen to a “hold” rating in a report issued on Saturday, Wall Street Zen reports.
Other research analysts also recently issued reports about the stock. Guggenheim started coverage on shares of Retension Pharmaceuticals in a research note on Monday, November 2nd. They set a “buy” rating and a $55.00 price target on the stock. Zacks Research initiated coverage on shares of Retension Pharmaceuticals in a research note on Wednesday, November 4th. They issued a “hold” rating for the company. Leerink Partners began coverage on shares of Retension Pharmaceuticals in a report on Tuesday, November 3rd. They set a “strong-buy” rating on the stock. Finally, Oppenheimer initiated coverage on shares of Retension Pharmaceuticals in a research report on Tuesday, November 3rd. They issued an “outperform” rating and a $50.00 target price on the stock. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $52.50.
View Our Latest Research Report on Retension Pharmaceuticals
Retension Pharmaceuticals Price Performance
RTSN opened at $12.27 on Friday. Retension Pharmaceuticals has a 12-month low of $9.66 and a 12-month high of $18.64.
Insiders Place Their Bets
In other news, CEO Eric L. Keller acquired 20,800 shares of the stock in a transaction dated Tuesday, October 13th. The stock was purchased at an average cost of $12.00 per share, with a total value of $249,600.00. Following the completion of the purchase, the chief executive officer owned 423,377 shares in the company, valued at approximately $5,080,524. The trade was a 5.17% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Franklin M. Berger bought 10,000 shares of the company’s stock in a transaction dated Tuesday, October 13th. The shares were purchased at an average price of $12.00 per share, with a total value of $120,000.00. Following the completion of the acquisition, the director owned 10,000 shares of the company’s stock, valued at $120,000. This trade represents a ? increase in their position. The SEC filing for this purchase provides additional information.
About Retension Pharmaceuticals
We are a clinical-stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases. Our product candidate, RTN-001, is a next-generation, once-daily, oral, small molecule phosphodiesterase-5 (“PDE-5”) inhibitor designed to reduce blood pressure by potentiating nitric oxide signaling, a key mechanism underlying the development and severity of hypertension. While first-generation PDE-5 inhibitors, such as Viagra (sildenafil), were originally studied in cardiovascular indications such as hypertension and angina, we believe they did not have adequate bioavailability and tissue penetration to impact the smooth muscle cells of the central vascular and cardiac tissues and thus failed to achieve clinically meaningful reductions in blood pressure.
Further Reading
- Five stocks we like better than Retension Pharmaceuticals
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Retension Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retension Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
